Getting Started | Velsipity® (Etrasimod)

This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Log Out

Pfizer Medicines

Therapy Areas

Explore Content

Events

Videos

Materials

Featured Articles

Let’s Connect

Supply

Alliance Healthcare

Off-contract claims

Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

Home

Unmet Need

Efficacy

Efficacy Home Page

Trial Design

Clinical Remission

Endoscopic Improvement

Corticosteroid-Free Remission

Isolated Proctitis

Bio/JAKi Subgroups Data

Induction Responders

Symptomatic Response

Bowel Urgency

Safety

Adverse events

Pooled and Interim Safety Data

Special Warnings and Precautions

Cardiac and Ocular Adverse Reactions

Getting Started

Contraindications and Interactions

Pre-first Dose Testing

Resources

Events

Materials

Videos

VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.¹

The convenience of one pill, once a day¹

Getting Started

One pill, once a day

Recommended dose:
2 mg orally once daily

The same dose right from the start - no titration required

Missed dose¹

If a dose is missed, the prescribed dose should be taken at the next scheduled time; the
next dose should not be doubled.

Dose interruption¹¹

If treatment is interrupted for 7 or more consecutive days, it is recommended to
resume treatment with food for the first 3 doses.

Contraindications:¹

Hypersensitivity to the active substance or to any of the excipients
Immunodeficient state
History in the last 6 months of MI, unstable angina pectoris, stroke, TIA, decompensated heart failure requiring hospitalisation, or NYHA Class III/IV heart failure
History or presence of Mobitz type II second-degree or third-degree AV block, sick sinus
syndrome, or sino-atrial block, unless patient has a functioning pacemaker
Severe active infections, active chronic infections such as hepatitis or tuberculosis
Active malignancies
Severe hepatic impairment
During pregnancy and in women of childbearing potential not using effective contraception

STARTING AND STOPPING TREATMENT

PRIOR TO FIRST DOSE:

Treatment should be initiated under the supervision of a physician experienced in the management of UC¹

Update immunisations in agreement with current immunisation guidelines prior to initiating VELSIPITY¹ - Live vaccines should be given at least 4 weeks prior to VELSIPITY initiation¹
Caution should be applied when VELSIPITY is initiated in patients receiving treatment
with a beta blocker because of the potential additive effects on lowering heart rate.
Similar caution should be applied if patients receive calcium channel blockers, QT
prolonging medicinal products, Class Ia and Class III anti-arrhythmic substances,
since co-administration of these substances with VELSIPITY may lead to additive
effects¹
Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be co-administered with caution because of the risk of additive immune system effects during such therapy¹
Women of childbearing potential: before initiation of treatment, women of childbearing
potential must be informed about the risk to the foetus, must have a negative
pregnancy test, and must use effective contraception during treatment¹
It is recommended that patients with a history of diabetes mellitus, uveitis, and/or underlying/co-existing retinal disease undergo an ophthalmic evaluation and have follow-up evaluations while receiving therapy.
It is recommended that VELSIPITY be administered with food for the first 3 days to attenuate potential transient heart rate lowering effects related to initiation of treatment. After that, it can be taken with or without food¹
Tablets should be swollowed whole with water and not be split, crushed or chewed because these methods have not been studied in clinical trials¹

Please consult the SmPC for further details on prescribing. Bradyarrythmia and atrioventricular conduction delays, infections and women of childbearing potential are each listed as special warnings and precautions for use.

The mean plasma elimination half-life of VELSIPITY is approximately 30 hours

AFTER THE LAST DOSE:

Women of childbearing potential should use effective contraception for at least 14 days
Vigilance for infection should be continued for up to 2 weeks
Use of live attenuated should be avoided during treatment and for at least 2 weeks after discontinuation due to risk of infection

Contraindications and interactions

See the interactions and special populations that should be considered before starting VELSIPITY.

EXPLORE CONTRAINDICATIONS AND INTERACTIONS

AV – atrioventricular; MI – myocardial infarction; NYHA – New York Heart Association; TIA – transient ischaemic attack

References:

VELSIPITY Summary of Product Characteristics

PP-V1A-GBR-0022. September 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search

for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

This website is brought to you by Pfizer Limited, a company registered in England

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024

You are now leaving PfizerPro

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd.

Pfizer accepts no responsibility for the content or services of the linked site.

PP-PFE-GBR-3858. November 2021

You are now leaving PfizerPro

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021